

LENZ & STAEHELIN ADVISES LONZA ON LARGE-SCALE COMMERCIAL INSTALLATION IN STEIN

Posted on 6 July 2022



Category: [Deal & transactions](#)

Tags: [Bär & Karrer](#), [Corrado Rampini](#), [Fabiano Menghini](#), [Jan Küng](#), [Kilian Muller](#), [Lenz & Staehelin](#), [lonza](#), [noemie ammann](#), [Rebecca Rötheli](#), [Slider](#)



Novartis Pharma Stein has sold a building right on part of its industry area in Stein to Lonza. The SIX-listed **Lonza Group** has announced that it plans to construct a large-scale, commercial drug product fill & finish facility in the Stein building. The investment will allow Lonza to provide customers with a complete and integrated end-to-end solution that includes commercial drug manufacturing for large-scale market supply. The new facility will be funded by an investment of approx. CHF 500 million and is expected to be completed in 2026.

[Lenz & Staehelin](#) is advising Lonza in this transaction. The team includes **Fabiano Menghini** (partner, co-head of real estate, pictured), associate **Rebecca Rötheli** as well as **Noémie Ammann** and **Jan Küng**.

[Bär & Karrer](#) acted as legal advisor to Novartis in this transaction. The team included **Corrado Rampini** and **Kilian Müller** (both real estate).



Corrado Rampini, partner Bär & Karrer